OTCMKTS:MPSYF MorphoSys (MPSYF) Stock Forecast, Price & News $30.18 0.00 (0.00%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$30.18▼$30.1850-Day Range$30.18▼$30.1852-Week Range$13.84▼$30.96VolumeN/AAverage Volume1,753 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsSEC FilingsShort InterestProfileChartCompetitorsFinancialsSEC FilingsShort Interest About MorphoSys (OTCMKTS:MPSYF) StockMorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More MPSYF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MPSYF Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive MPSYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MPSYF CUSIPN/A CIK1340243 Webwww.morphosys.com Phone(498) 989-9270FaxN/AEmployees544Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Jean-Paul Kress M.D. (Age 58)Chairman of Management Board, MD & CEO Comp: $2.17MDr. Lucinda Crabtree Ph.D. (Age 44)CFO & Member of Management Board Ms. Charlotte Lohmann (Age 53)Chief Legal Officer & Member of Management Board Mr. Klaus De WallHead of Accounting & TaxMs. Lara Smith WeberHead of Controlling, Corp. Fin. & Corp. Devel.Dr. Margit UrbanHead of Discovery Alliances & TechnologiesDr. Anja PomrehnSr. VP & Head of Investor RelationsMr. Thomas BiegiVP & Head of Corp. CommunicationsMs. Maria CastresanaSr. VP & Global Head of HRDr. Barbara Krebs-Pohl Ph.D.Chief Bus. OfficerMore ExecutivesKey Competitors3SBioOTCMKTS:TRSBF60 Degrees Pharmaceuticals, Inc. WarrantNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFAgentixOTCMKTS:AGTXView All Competitors MPSYF Stock - Frequently Asked Questions How have MPSYF shares performed in 2023? MorphoSys' stock was trading at $14.18 at the start of the year. Since then, MPSYF shares have increased by 112.8% and is now trading at $30.18. View the best growth stocks for 2023 here. What is MorphoSys' stock symbol? MorphoSys trades on the OTCMKTS under the ticker symbol "MPSYF." How do I buy shares of MorphoSys? Shares of MPSYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MorphoSys' stock price today? One share of MPSYF stock can currently be purchased for approximately $30.18. How many employees does MorphoSys have? The company employs 544 workers across the globe. How can I contact MorphoSys? MorphoSys' mailing address is Semmelweisstrasse 7, Planegg, Bayern (Bavaria). The official website for the company is www.morphosys.com. The company can be reached via phone at (498) 989-9270. This page (OTCMKTS:MPSYF) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.